Bringing New Blood to the Anemia Market

Sales of erythropoiesis-stimulating agents for treating anemia totaled approximately $11.5 billion in 2008, about $7 billion in the US. Any emerging venture expecting to sink its teeth into this huge market will need to prove its future product offers greater ease of manufacture, storage, and administration, and lower price and a better safety profile compared with the widely used biologics, while overcoming the higher barriers to approval set by the FDA.

The latest Twilight movie opened last month to one of the biggest box office takes ever. The red-blood-cell-craving screen vampires didn't offer their anemic victims any pharmaceutical relief, but several biotechs hope to generate their own brand of box office boffo from real-life anemia patients. But making a vampire movie might be an easier path to commercial success.

The market for erythropoiesis-stimulating agents (ESAs) appears deceptively wide open. In the US, the National Institutes of Health reports...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip